ClinicalTrials.gg
RecruitingNCT06619288Updated Oct 1, 2024

Good-first: B/F/TAF As First-line ART

An observational study in HIV Infection, sponsored by Affiliated Hospital of Nantong University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.

Sponsored by Affiliated Hospital of Nantong University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 4 months ago, but the record still lists the study as recruiting.
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
630
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 67 studies in HIV Infections with a site in China — 10 open to participants now, 10 under way, none of them phase 3. HIV Infections · China.

Planned enrollment
5th of 16
630 · median 435
Started
2024
with 2 others
Observational
16 of 67
5 open now
Registered
61st of 67
by date

Among the 67 studies in HIV Infections with a site in China, this one is the 5th largest by planned enrollment of the 16 observational ones that give a count, is one of 3 that started in 2024, is one of 16 observational ones, and was the 61st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

10 of the 67 studies in HIV Infections with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in HIV Infections with a site in China, or all of them as a file.
02

Study summary

This is a multicohort study conducted at Affiliated Hospital of Nantong University, and Nantong Third Peoples Hospital (Designated Hospital for HIV/AIDS Treatment of Nantong City), China. The study would involve 630 patients initiating HIV treatment, divided into six cohorts. The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.

Read the detailed description

Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) is recommended for initiating antiretroviral therapy (ART) in newly diagnosed HIV patients, including those with advanced disease. However, clinical data for this group is limited, and the high cost of B/F/TAF may hinder its widespread use as a first-line treatment.

This study aim to gather real-world evidence on the clinical practice of B/F/TAF as a first-line ART and address the knowledge gap regarding its cost-effectiveness. A multicohort study at the Designated Hospital for HIV/AIDS Treatment of Nantong City, China, involves 630 patients initiating HIV treatment, divided into six cohorts. There are 230 prospective patients on B/F/TAF (115 late presenters with CD4; 350 cells/μL or an AIDS-defining event, and 115 early presenters). Additionally, there are 400 retrospective patients on either tenofovir+lamivudine+efavirenz (TDF+3TC+EFV, 100 for each presentation group) or dolutegravir/lamivudine (DTG/3TC, 100 for each presentation group). The enrollment period for the prospective cohort is from July 2024 to June 2025, while the enrollment period for the retrospective cohort is from January 2020 to June 2023.

Data will be collected at baseline and at specific intervals over 48 weeks using electronic health records and patient-reported outcomes. Clinical data include time from diagnosis to ART initiation, plasma viral load (VL), CD4 count, adverse events, treatment adherence, and quality of life (QoL). QoL improvements will be assessed through questionnaires. Cost data will be collected following healthcare reporting standards. A microsimulation model will be adapted. The cost-effectiveness of B/F/TAF, compared to the other regimens, will be evaluated using clinical cohort data and modeling techniques to project long-term economic outcomes.

This study was approved by the ethics committee of Nantong Third Peoples Hospital. Consent will also be obtained from the participants during the study process.

This study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

03

Conditions studied

  • HIV Infection

Browse trials for

Keywords

  • B/F/TAF
  • TDF+3TC+EFV
  • DTG/3TC
  • Cohort study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study population will consist of HIV-infected patients, including those who present in the early stages of infection as well as those with late-stage or advanced presentations. These individuals will encompass a wide range of clinical scenarios to ensure the findings are applicable to diverse patient populations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults (≥18 years) diagnosed with /AIDS, ART-naive, from July 2024 to June 2025 (prospective) or January 2020 to June 2023 (retrospective).
  2. Eligible for ART initiation with B/F/TAF or previously treated with TDF+3TC+EFV or DTG/3TC.
  3. Willing to adhere to study procedures and follow-up visits or have complete electronic health records (EHRs).

Exclusion criteria

Exclusion Criteria:

  1. Severe renal impairment ( \< 50 mL/min).
  2. co-infection or severe hepatic impairment ( Class C).
  3. Active tuberculosis (TB).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
630 participants (estimated)
Patient registry
No

Groups and cohorts

  • HIV early presenters (TDF+3TC+EFV)

    100 HIV-infected early presenters diagnosed between Jan 2020 and Jun 2023.

    Drug: TDF+3TC+EFV

  • HIV late presenters (TDF+3TC+EFV)

    100 HIV-infected late presenters diagnosed between Jan 2020 and Jun 2023.

    Drug: TDF+3TC+EFV

  • HIV early presenters(DTG/3TC)

    100 HIV-infected early presenters diagnosed between Jan 2020 and Jun 2023.

    Drug: DTG/3TC

  • HIV late presenters (DTG/3TC)

    100 HIV-infected late presenters diagnosed between Jan 2020 and Jun 2023.

    Drug: DTG/3TC

  • HIV early presenters (B/F/TAF)

    115 HIV-infected early presenters diagnosed between Jul 2024 and Jun 2025.

    Drug: B/F/TAF

  • HIV late presenters (B/F/TAF)

    115 HIV-infected late presenters diagnosed between Jul 2024 and Jun 2025.

    Drug: B/F/TAF

Interventions

06

What researchers measure

Primary outcomes

  1. Rate of participants with virologic suppression

    Virologic suppression is defined as a plasma viral load (HIV RNA) of less than 50 copies/mL.

    Time frame: At 12 weeks, 24 weeks, and 48 weeks from the initiation of ART.

  2. Change of CD4 count

    The percentage change in CD4+ T cell count from baseline after initiating ART, stratified by patients with lower versus higher baseline CD4+ levels.

    Time frame: At 12 weeks, 24 weeks, and 48 weeks from the initiation of ART.

  3. Rate of immune reconstitution in late presenters

    Immune reconstitution is defined as an immunological response in HIV late presenters, characterized by a CD4+ T cell count increase of at least 20% from baseline or reaching at least 350 cells/μL at 48 weeks, accompanied by an undetectable viral load.

    Time frame: At 48 weeks from the initiation of ART.

Secondary outcomes

  1. Rate of treatment discontinuation

    Throughout the entire follow-up period, there were instances of loss to follow-up or death due to other illnesses. If a subject experiences significant adverse reactions after taking the medication, it is necessary to discontinue the medication.

    Time frame: From the initiation of ART until the end of the study, with an estimated period of assessment up to 104 weeks. This period includes monitoring from the date of ART initiation until the date of treatment discontinuation or study end.

  2. Number of adverse events

    Adverse events are mainly divided into five categories: central nervous system symptoms, which include headache, dizziness, insomnia, difficulty concentrating, mood changes, or mental confusion; gastrointestinal symptoms, such as nausea, vomiting, diarrhea, abdominal pain, or dyspepsia; hematologic symptoms, which involve low levels of red blood cells or hemoglobin, leading to fatigue, weakness, or pallor; hepatotoxicity, indicated by elevated liver enzyme levels, jaundice, or other signs of liver dysfunction; and dermatitis, which includes rash, itching, erythema, or dry skin.

    Time frame: From the initiation of ART until the end of the study, with an estimated period of assessment up to 104 weeks. This period includes monitoring from the date of ART initiation until the date of treatment discontinuation or study end.

  3. QoL assessment

    Quality of Life (QoL) is assessed using the EQ-5D-5L scale, a standardized instrument developed by the EuroQol Group. It measures general health across five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) with five levels of severity each. The index score ranges from -0.59 to 1, with higher scores indicating better health status.

    Time frame: Assessed at baseline, and at 12, 24, and 48 weeks.

  4. HIV symptom assessment

    The HIV Symptom Index (HIV-SI) is used to assess the prevalence and severity of HIV-related symptoms. Scores range from 0 to 80, with higher scores indicating a greater burden of symptoms.

    Time frame: Assessed at baseline, and at 12, 24, and 48 weeks.

  5. Mental health assessment

    People living with HIV (PLHIV) have a risk of experiencing depressive symptoms that is three times higher than that of the general population. The Patient Health Questionnaire-9 (PHQ-9), a self-administered scale, is used for diagnosing and monitoring depression. Scores on the PHQ-9 range from 0 to 27, with higher scores indicating more severe levels of depression. If a patient presents with moderate depressive symptoms (PHQ-9 score \> 9), he or she will be referred to a psychiatrist.

    Time frame: Assessed at baseline, and at 12, 24, and 48 weeks.

  6. Cardiovascular risk assessment

    Cardiovascular risk assessment is an essential component of clinical practice for people living with HIV (PLHIV). The Framingham Risk Score is used to estimate the 10-year cardiovascular risk of an individual. Scores range from 0% to 30% or higher, with higher scores indicating a greater cardiovascular risk.

    Time frame: Assessed at baseline, and at 12, 24, and 48 weeks.

Other outcomes

  1. Change of body weight

    This metric represents the percentage change in body weight from the baseline measurement.

    Time frame: At 12 weeks, 24 weeks and 48 weeks from the initiation of ART.

  2. Change of LDL

    Monitoring changes in low-density lipoprotein (LDL) cholesterol levels helps assess cardiovascular risk and the impact of ART on lipid profiles over time.

    Time frame: At 12 weeks, 24 weeks and 48 weeks from the initiation of ART.

  3. Change of eGFR

    Estimated glomerular filtration rate (eGFR) calculated using serum creatinine levels is used to assess kidney function over time and indicates how well the kidneys are filtering waste from the blood. Changes in eGFR can signal improvements or declines in renal function.

    Time frame: At 12 weeks, 24 weeks and 48 weeks from the initiation of ART.

07

Study locations

1 of 1 sites recruiting
  • Nantong Third Peoples Hospital
    Nantong, Jiangsu 226006, China
    Recruiting
    • Mei-Yin Zou, MD · Contactzoumeiyin@126.com · +86-159-5082-4526
    • Mei-Yin Zou, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jun 2025, 11 months after the start.

Of 187 non-industry observational studies under HIV Infections, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 69. This study's planned 11 months is below that.

Counting every sponsor, half of 201 studies reached it within 38 months; a quarter within 16 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Oct 1, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jun 30, 2025
CompletionEst.
Jun 30, 2026
Last update
Oct 1, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 1, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06619288
Lead sponsor
Affiliated Hospital of Nantong University
Collaborators
Nantong Third Peoples Hospital
Responsible party
Gang Qin, MD, PhD (Associate Professor, Affiliated Hospital of Nantong University) — Principal investigator
First posted
Oct 1, 2024
Start date
Jul 1, 2024
Primary completion
Jun 30, 2025 (estimated)
Completion
Jun 30, 2026 (estimated)
Last update
Oct 1, 2024

Study contacts

Gang Qin, MD, PhD
Contact
tonygqin@ntu.edu.cn
+86-189-1228-8106
Gang Qin, MD, PhD
study chair · Affiliated Hospital of Nantong University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion